益生菌联合美沙拉嗪对溃疡性结肠炎患者疾病活动指数及肠道菌群的影响OA
Effects of Probiotics Combined with Mesalazine on Disease Activity Index and Intestinal Flora in Patients with Ulcerative Colitis
目的:探讨益生菌联合美沙拉嗪对溃疡性结肠炎(UC)患者疾病活动指数(DAI)及肠道菌群的影响.方法:将2021年4月至2023年12月我院收治的的UC患者84例随机分为联合组和单一组,每组42例.单一组患者采用美沙拉嗪治疗,联合组患者加用益生菌治疗,均连续服用2个月,对比2组患者的临床疗效、炎症指标[C反应蛋白(CRP)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)]、肠道菌群数量、DAI评分、免疫功能及不良反应发生情况.结果:联合组患者治疗总有效率较单一组高(P<0.05);2组患者治疗后CRP、IL-1β、TNF-α水平均低于治疗前,且联合组低于单一组(P<0.05);相比于治疗前,2组患者治疗后双歧杆菌、乳杆菌数量和B/E值均提高,大肠埃希菌数量下降,且联合组双歧杆菌、乳杆菌数量和B/E值高于单一组,大肠埃希菌数量较单一组低(P<0.05);2组患者治疗后DAI评分、CD8+较治疗前低,CD4+、CD4+/CD8+较治疗前高,且联合组DAI评分、CD8+低于单一组,CD4+、CD4+/CD8+高于单一组(P<0.05);治疗期间2组患者均无药物相关不良反应发生.结论:益生菌联合美沙拉嗪治疗UC安全性较高,能够提高治疗效果,更好的改善机体炎症反应,改善肠道菌群,提高免疫功能.
Objective To investigate the effects of probiotics combined with mesalazine on the disease activ-ity index(DAI)and intestinal flora in patients with ulcerative colitis(UC).Methods A total of 84 UC patients admitted to our hospital from April 2021 to December 2023 were randomly divided into the combination group and the monotherapy group,with 42 cases in each group.The monotherapy group received mesalazine alone,while the combination group was additionally treated with probiotics.Both groups received continuous treatment for 2 months.Clinical efficacy,inflammatory markers[C-reactive protein(CRP),interleukin-1β(IL-1β),tumor necrosis factor-α(TNF-α)],counts of intestinal flora,DAI scores,immune function and adverse reactions were compared between the two groups.Results The total effective rate in the combina-tion group was higher than that in the monotherapy group(P<0.05).After treatment,the levels of CRP,IL-1β and TNF-α in both groups were lower than those before treatment,and the levels in the combination group were lower than those in the monotherapy group(P<0.05).Compared with before treatment,the counts of Bifidobacterium,Lactobacillus and B/E ratio in both groups were increased,while the count of Escherichia coli was decreased.Moreover,the counts of Bifidobacterium,Lactobacillus and B/E ratio in the combination group were higher,and the count of Escherichia coli was lower than those in the monotherapy group(P<0.05).After treatment,DAI scores and CD8⁺ levels in both groups were lower than those before treatment,while CD4⁺ levels and CD4⁺/CD8⁺ ratio were higher.Furthermore,DAI scores and CD8⁺ levels in the combination group were lower,and CD4⁺ levels and CD4⁺/CD8⁺ ratio were higher than those in the monotherapy group(P<0.05).No drug-related adverse reactions occurred in either group during treatment.Conclusion Probiot-ics combined with mesalazine is safe in the treatment of UC,and can improve therapeutic efficacy,alleviate sys-temic inflammatory response,regulate intestinal flora and enhance immune function.
柳淼
焦作市人民医院消化一区(河南 焦作 454000)
溃疡性结肠炎益生菌美沙拉嗪疾病活动指数肠道菌群
Ulcerative colitisProbioticsMesalazineDisease activity indexIntestinal flora
《中国肛肠病杂志》 2026 (4)
32-35,4
评论